» Articles » PMID: 32806947

Patients with Type 1 Diabetes Treated with Insulin Pumps Need Widely Heterogeneous Basal Rate Profiles Ranging from Negligible to Pronounced Diurnal Variability

Overview
Specialty Endocrinology
Date 2020 Aug 19
PMID 32806947
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pump-treated patients with type 1 diabetes have widely differing basal insulin infusion profiles. We analyzed consequences of such heterogeneity for glycemic control under fasting conditions.

Methods: Data from 339 adult patients with type 1 diabetes on insulin pump therapy undergoing a 24-hour fast (basal rate test) were retrospectively analyzed. Hourly programmed basal insulin infusion rates and plasma glucose concentrations as well as their proportions within, below, or above arbitrarily defined target ranges were assessed for specific periods of the day (eg, 1-7 hours, "dawn" period, 16-19 hours, "dusk" period, reference period 20-1 hours/10-14 hours), by tertiles of a predefined "dawn" index (mean basal insulin infusion rate during the "dawn" divided by the reference periods).

Results: The "dawn" index varied interindividually from 0.7 to 4.4. Basal insulin infusion profiles exhibited substantial differences ( = .011), especially overnight. Despite higher insulin infusion rates at 4 and 6.45 hours, patients with the most pronounced "dawn" phenomenon exhibited higher plasma glucose concentrations at those time points ( < .012). Patients with a marked "dawn" phenomenon exhibited a lower probability for low (<4.4 mmol/L) and a higher probability of high values (>7.2 mmol/L) during the dawn period (all values <.01).

Conclusions: We observe substantial interindividual heterogeneity in the "dawn" phenomenon. However, widely different empirically derived basal insulin infusion profiles appear appropriate for individual patients, as indicated by similar plasma glucose concentrations, mainly in the target range, during a 24-hour fasting period.

Citing Articles

Insulin Requirements According to Sex and Weight in a Population of 9036 Adult Persons With Type 1 Diabetes Using Closed-Loop Insulin Delivery.

Lebbad H, Desir C, Vesin A, Adenis A, Charpentier G, Benhamou P J Diabetes Sci Technol. 2024; :19322968241252366.

PMID: 38804537 PMC: 11571726. DOI: 10.1177/19322968241252366.


A probabilistic computation framework to estimate the dawn phenomenon in type 2 diabetes using continuous glucose monitoring.

Barua S, Glantz N, Larez A, Bevier W, Sabharwal A, Kerr D Sci Rep. 2024; 14(1):2915.

PMID: 38316854 PMC: 10844336. DOI: 10.1038/s41598-024-52461-1.


Recovery Phase Nutrition and Insulin Strategies for a Collegiate Distance Runner with Type 1 Diabetes Mellitus: A Case Study.

Schroeder A, Rosenkranz R, Yarrow L, Haub M, Rosenkranz S Sports (Basel). 2023; 11(11).

PMID: 37999431 PMC: 10674803. DOI: 10.3390/sports11110214.


Insulin Requirements for Basal and Auto-Correction Insulin Delivery in Advanced Hybrid Closed-Loop System: 4193 Days' Real-World Data of Children in Two Different Age Groups.

Karakus K, Yesiltepe Mutlu G, Gokce T, Eviz E, Can E, Muradoglu S J Diabetes Sci Technol. 2022; 18(2):445-453.

PMID: 35771030 PMC: 10973851. DOI: 10.1177/19322968221106194.


Insulin Titration Guidelines for Patients With Type 1 Diabetes: It Is About Time!.

Walsh J, Roberts R, Bailey T, Heinemann L J Diabetes Sci Technol. 2022; 17(4):1066-1076.

PMID: 35369773 PMC: 10348003. DOI: 10.1177/19322968221087261.


References
1.
Leelarathna L, Thabit H, Hartnell S, Willinska M, Dellweg S, Benesch C . Rapid Benefits of Structured Optimization and Sensor-Augmented Insulin Pump Therapy in Adults With Type 1 Diabetes. J Diabetes Sci Technol. 2016; 11(1):180-181. PMC: 5375064. DOI: 10.1177/1932296816654715. View

2.
Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P . Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia. 1990; 33(1):52-9. DOI: 10.1007/BF00586461. View

3.
Tauschmann M, Thabit H, Bally L, Allen J, Hartnell S, Wilinska M . Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 2018; 392(10155):1321-1329. PMC: 6182127. DOI: 10.1016/S0140-6736(18)31947-0. View

4.
Bolli G, Gerich J . The "dawn phenomenon"--a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med. 1984; 310(12):746-50. DOI: 10.1056/NEJM198403223101203. View

5.
Porcellati F, Lucidi P, Bolli G, Fanelli C . Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. Diabetes Care. 2013; 36(12):3860-2. PMC: 3836156. DOI: 10.2337/dc13-2088. View